Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07217067 · ClinicalTrials.gov registry record · Phase 2
A Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of PKN605 in Participants With Atrial Fibrillation
A Phase 2 study of Atrial Fibrillation, sponsored by Novartis Pharmaceuticals.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 165
- Enrollment target
- 20
- Study locations
NCT07217067: Recruiting Phase 2 study of Atrial Fibrillation, sponsored by Novartis Pharmaceuticals.
NCT07217067 is a Phase 2 study of Atrial Fibrillation that is actively recruiting participants, run by Novartis Pharmaceuticals. The registered enrollment target is 165 participants, below the 2,996-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (94% lower). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07217067, a Phase 2 study of Atrial Fibrillation, is actively recruiting participants, sponsored by Novartis Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 165 participants
- Enrollment target
- 20
- Study locations
Study Summary
A randomized, placebo-controlled, participant-and investigator-blinded study to evaluate the efficacy in reducing atrial fibrillation burden as well as the safety, tolerability and pharmacokinetics of PKN605 in participants with atrial fibrillation
Primary Outcome
Defined as the amount of time spent in atrial fibrillation as a proportion of the analyzable monitoring time
Conditions Studied
Interventions
- OTHER Placebo
- DRUG PKN605
Study Locations (20)
Other
- Novartis Investigative Site - Xi'an
- Novartis Investigative Site - Bad Homburg
- Novartis Investigative Site - Berlin
- Novartis Investigative Site - Berlin
- Novartis Investigative Site - Hamburg
- Novartis Investigative Site - Hamburg
Quebec
- Novartis Investigative Site - Montreal
- Novartis Investigative Site - Montreal
- Novartis Investigative Site - Montreal
- Novartis Investigative Site - Québec
- Novartis Investigative Site - Sherbrooke
Ontario
- Novartis Investigative Site - London
- Novartis Investigative Site - Newmarket
- Novartis Investigative Site - Toronto
Mississippi
- Cardiology Associates of North MS - Tupelo
New York
- Weill Cornell Medical Center - New York
Utah
- Intermountain Medical Center - Murray
Washington
- Swedish Heart and Vascular Clinic - Seattle
Beijing Municipality
- Novartis Investigative Site - Beijing
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 165 participants |
| Start Date | 2025-10-28 |
| Est. Completion | 2027-09-09 |
| Phase | Phase 2 |
What NCT07217067 shows while recruiting
NCT07217067 is an interventional study that assigns participants to a tested intervention. The registered 165 participants enrollment target is mid-sized for trials with a published cap, below the 2,996-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (94% lower).
The record links to 1 condition, with Atrial Fibrillation appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07217067 names 20 study sites across 9 states, led by Other, Quebec, Ontario.
Frequently Asked Questions
What is clinical trial NCT07217067 about?
NCT07217067 is a clinical study titled "A Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of PKN605 in Participants With Atrial Fibrillation". A randomized, placebo-controlled, participant-and investigator-blinded study to evaluate the efficacy in reducing atrial fibrillation burden as well as the safety, tolerability and pharmacokinetics of PKN605 in participants with atrial fibrillation
What is the current status of trial NCT07217067?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 165 participants. The study started on 2025-10-28. Estimated completion is 2027-09-09.
What conditions does trial NCT07217067 study?
This clinical trial studies the following conditions: Atrial Fibrillation.
What interventions are being tested in trial NCT07217067?
The interventions under investigation include: Placebo (OTHER), PKN605 (DRUG).
Who is sponsoring clinical trial NCT07217067?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07217067 being conducted?
This trial has 20 study locations across Mississippi, New York, Utah, Washington, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atrial Fibrillation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07217067's enrollment target sits among peer trials
165 114th of 202 higher than 88 of 202 other Atrial Fibrillation trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Atrial Fibrillation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation
RECRUITING · Phase 2
-
Amiodarone for the Prevention of Atrial Fibrillation After Minimally Invasive Esophagectomy in Patients With Esophageal Cancer
RECRUITING · Phase 2
-
Chloroquine for Patients With Symptomatic Persistent Atrial Fibrillation: A Prospective Pilot Study
RECRUITING · Phase 2
-
A Study of Stellate Ganglion Block for Prevention of Atrial Fibrillation
RECRUITING · Phase 2
-
ECG Validation Study
ACTIVE NOT RECRUITING · Phase 2
-
A Study of IV HBI-3000 for the Conversion Recent Onset Atrial Fibrillation (AF)
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02387255 · 165 participants
Magnetic Resonance Elastography in Patients With Abdominal Aortic Aneurysms
- NCT03351348 · 165 participants · Phase 3
Bupivacaine vs Placebo for Unilateral Mastectomy Surgical Site Post-operative Pain Control
- NCT04289571 · 165 participants · Phase 1
Virtual Reality Mobility Assessment of Functional Vision in Retinal Disease
- NCT04458584 · 165 participants
Restoration of Thumb Strength and Function in Basal Joint Arthritis: A Comparative Effectiveness Trial (RESTART)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI